In 2011 the proven way to keep an adult with prediabetes from developing type 2 diabetes was the Diabetes Prevention Program, a structured course of lifestyle change delivered in person OM1 OM2. Classes met at fixed times and places, which limited how many people could join and how many kept coming OM1. Digital wellness apps were easier to hand out, but they gave employers and health plans little clinical evidence and no human support OM1. The employer or health plan paid for a program, and each eligible member still had to decide to enroll and keep taking part OM1.
Omada Health
Omada built coached care for diabetes, where a digital program adds to what employers pay, came to depend on Cigna inside the same benefits channels Hinge used, added joint and back pain after Hinge was the default, and kept a coach-led cost base that held its margin far below Hinge's.
Why Omada Health lost to Hinge Health
- 1 · 2011–15Began in diabetes preventionA coached, device-supported online version of the Diabetes Prevention Program; PHTI later found digital diabetes tools raised spending.Professional Services
- 2 · 2013–17Clinical proof that rivals matchedPeer-reviewed weight and blood-sugar results and CDC recognition; its MSK program was later rated comparable to Hinge's.
- 3 · 2016–25Same channels, concentrated in CignaHealth plans and PBMs resold its programs; two Cigna affiliates were 65% of 2025 revenue.Distribution Partnerships
- 4 · 2020–25MSK as a late add-onVideo physical therapy from 2020, sold as one program among several after Hinge had become the default vendor.Usage-Based Pricing
- 5 · 2022–25Coach-led care, lower marginsHealth coaches, video physical therapists and cellular devices; gross margin 66% and a $12M operating loss in 2025.Professional Services
Versus Hinge Health: Hinge Health chose a condition where home exercise replaces paid clinic care, became the one MSK vendor inside most of its partners' employers, and automated care so costs stayed flat as members grew HGX-11 H6 HGX-8. Omada built human coaching for diabetes and other chronic conditions, added MSK later as one program in a bundle, and came to depend on two Cigna affiliates for most of its revenue HGX-10 OM2.
Arena: Market Conditions Before Omada Health
How each step happened
Step 1 of 5 · 2011–15
Began in diabetes prevention
A proven clinical program, moved online
Omada started from a program that already worked in person. Co-founder Sean Duffy drew on IDEO's design practice and on the Diabetes Prevention Program, and coached some early members himself HGX-10. Omada delivered the program remotely: a dedicated health coach for the whole program, lessons and goal setting, and connected devices such as scales that send readings automatically OM1 OM2. Its filing states the belief behind the design: "human relationships and empathy are fundamental drivers of sustainable behavior change" OM2. Technology was there to support a care relationship, not replace it OM1.
The choice made Omada a care service rather than an app, and it tied the business to prevention and diabetes. In that category a program is bought on top of the care members already receive. In 2024 the independent Peterson Health Technology Institute (PHTI) reviewed eight digital diabetes tools, Omada's among them, and found they lowered blood sugar too little to matter clinically while increasing spending, by $484 to $2,002 per patient a year for commercial insurers depending on the type of tool HGX-12. Omada had picked a condition where its program added to what buyers paid.
Rivals Hinge Health chose joint and back pain, where guided home exercise can replace clinic physical therapy; PHTI found in 2024 that programs guided by physical therapists matched in-person therapy at lower total spending H2 HGX-11. In diabetes Omada competed with Livongo (part of Teladoc), Virta and others; PHTI named Virta the exception among the tools it reviewed OM2 HGX-12.
Step 2 of 5 · 2013–17
Clinical proof that rivals matched
Benefits buyers needed more than app engagement before they would pay for a chronic-care program, so Omada invested in evidence OM1. It published peer-reviewed results on weight and blood sugar, one of the first digital programs to do so, and some of its prevention deployments earned recognition under the CDC's Diabetes Prevention Recognition Program, which sets quality and outcome standards HGX-10 OM2. Accreditations for its diabetes and other programs followed, and by 2025 it counted 30 peer-reviewed publications OM2 HGX-10.
The evidence made Omada credible to health plans and employers responsible for health and cost outcomes, and it did not set Omada apart from Hinge where the two met. When PHTI reviewed digital programs for joint and back pain in 2024, it placed Omada's in the same group as Hinge's, Sword's and Vori's: comparable to in-person physical therapy on pain and function, at lower total spending HGX-11. Both companies could show buyers clinical results. The contest was decided elsewhere.
Rivals Hinge Health published knee (2018) and back (2019) trials, then a 2022 claims analysis across 136 employer groups estimating $2,387 saved per enrolled member H4 HGX-3 HGX-4. Livongo, Virta and other virtual-care suppliers also publish outcomes OM1.
Step 3 of 5 · 2016–25
Same channels, concentrated in Cigna
From 2016 Omada built distribution through health plans and pharmacy benefit managers (PBMs), which offer its programs to the employers and covered populations they already serve OM1 OM2. The route saved an employer contracting and implementation work and put several conditions on one menu OM2. Blue Cross Blue Shield of Massachusetts listed Omada in a portfolio for large self-insured employers, beside Livongo and, from 2019, Hinge HGX-3. By 2025 Omada's partners included CVS Caremark and Cigna's EncircleRx program GFC-7.
The channel concentrated. Sales from or through Omada's five largest health plan and PBM partners rose from 68% of revenue in 2023 to 77% in 2025, and two partners, both affiliates of The Cigna Group, accounted for 32% and 33% of 2025 revenue OM2. Partners work with Omada on a non-exclusive basis OM2. Omada reached employers through a few large intermediaries that decide which vendors to show them, and in joint and back pain it did not become the vendor those intermediaries' employers picked.
Rivals Hinge Health took 79% of its 2024 revenue through its partners and says that when it signs one it typically wins "a large majority of the employers using that partner who go on to select a digital MSK solution" H6. Its largest partners in 2025, HCSC, Elevance and Aetna, each accounted for between 10% and 18% of revenue H9.
Step 4 of 5 · 2020–25
MSK as a late add-on
Omada launched its program for joint and back pain in 2020, the year Hinge said four in five employers offering digital MSK care used it OM2 HGX-2. Omada for MSK came from the acquisition of Physera, a video physical-therapy service: a member is matched with a dedicated physical therapist, seen by video and chat, and assessed through video form analysis and phone-camera range-of-motion checks HGX-13 OM2. It arrived as one program among several, sold to buyers who already bought Omada's prevention and diabetes care OM2.
Omada grew across conditions rather than deeper into one. Its filing says "the significant overlap across these chronic conditions created a natural growth avenue" from prevention and weight to diabetes and hypertension OM2. Its pricing follows members: legacy contracts combined an upfront enrollment fee with monthly fees tied to outcomes or milestones, and newer contracts bill monthly for each member who completes a minimum number of program activities OM2. Customers stayed, with average three-year retention above 90% OM2. From 2023 a GLP-1 Care Track added coaching for members taking the new weight-loss drugs, and by the end of 2025 Omada had supported more than 150,000 of them GFC-4 GFC-6. In 2025 its weight, diabetes and hypertension programs each grew revenue by 45% or more GFC-6. Joint and back pain, where Hinge was already the employer's usual choice, stayed a side program.
Rivals Hinge Health is most often the only digital MSK provider its clients offer, on contracts averaging three years, and raised annual enrollment of eligible lives from 2.9% in 2022 to 3.4% in 2024 H6.
Step 5 of 5 · 2022–25
Coach-led care, lower margins
The human care model from step 1 set Omada's cost base. Its Care Teams of health coaches, specialists and physical therapists stay with members through their programs, and most of its devices are cellular-connected scales and monitors shipped to each member OM2. Omada has made that labor more productive. In 2025 members grew 55% to 886,000 while cost of services rose 22%, mostly from personnel costs, and gross margin reached 65.7% from 60.6%, which the company attributes to care-team efficiency work and tools that help coaches answer messages OM2. It still posted a $12M operating loss on $260M of revenue HGX-9.
Omada became a large business. It went public in June 2025 and ended that year with more than 2,000 customers, revenue up 53% and nearly two million people supported since launch HGX-10 OM2. It lost this comparison because its choices added up: a condition where a program adds to spending, a channel concentrated in one partner group, joint and back pain as a late add-on, and a coach-led service that keeps people at the center of every member's care. In the same year Hinge served 47% more members while keeping care-team costs flat HGX-8.
Rivals Hinge Health replaced its sensor kits with the member's own phone camera, estimates its platform cut care-team hours about 97% against traditional physical therapy, and reported an 83% gross margin on $588M of 2025 revenue H11 H9 HGX-8.
Key dates
- 2011Founded to deliver diabetes prevention online
- 2013First peer-reviewed outcomes
- 2015Norwest leads the Series C HGX-10
- 2016Health-plan and PBM distribution begins
- 2019-01BCBS Massachusetts adds Hinge beside Omada HGX-3
- 2020Omada for MSK launches with video physical therapy OM2
- 2020-02Hinge says four in five digital-MSK employers use it HGX-2
- 2023391,000 members End of year; top five partners 68% of revenue OM2
- 2023-05GLP-1 Care Track launches GFC-4
- 2024$169.8M revenue Full year; gross margin 60.6%; 572,000 members OM2
- 2024-03PHTI finds digital diabetes tools raise spending HGX-12
- 2024-06PHTI rates Omada's MSK program with Hinge's HGX-11
- 2025$260M revenue Full year, +53% year over year; gross margin 65.7%; 886,000 members OM2 HGX-9
- 2025Two Cigna affiliates supply 32% and 33% of revenue OM2
- 2025-06Initial public offering HGX-10
- 2025-11GLP-1 prescribing added GFC-6
Sources
Oldest first.
- H4 Effects of a 12-Week Digital Care Program for Chronic Knee Pain: Randomized Controlled Trial. Primary source
- HGX-3 Hinge Health partners with BCBS of Massachusetts, reveals results of clinical study. Trade report
- HGX-2 Hinge Health, the digital solution for chronic back and joint pain, closes $90M Series C. Trade report
- HGX-4 Hinge Health surpasses 1,000 enterprise customers now accessible to 21 million lives. Company release
- GFC-4 Omada Health Launches GLP-1-Specific Program for Patients Battling Chronic Obesity. Company press release
- HGX-12 New Report Finds That Digital Diabetes Management Tools Fail to Deliver Meaningful Health Benefits to Patients While Increasing Spending. Independent assessment
- HGX-11 New Analysis: Virtual Musculoskeletal Solutions Improve Health Outcomes and Lower Costs. Independent assessment
- H2 10 years in and we’re just getting started. Primary source
- HGX-13 Hinge Health revenue, funding & growth rate. Analyst report
- H6 Registration statement on Form S-1. Primary source
- GFC-5 Omada Health, Inc. Form S-1. Registration statement
- H11 Hinge Health: Reimagining possibilities and better outcomes with virtual care. Investor analysis and participant account
- OM1 Form S-1/A. Registration statement
- GFC-7 Omada grows revenue, membership in public earnings debut. Trade press report with management quotes
- HGX-10 Built to Bend the Curve: A Decade with Omada Health. Investor essay
- HGX-8 Hinge Health Q4 2025 earnings call transcript. Earnings call transcript
- HGX-9 Omada Health Reports Fourth Quarter and Full-Year 2025 Results. Filing
- H9 2025 annual report on Form 10-K. Primary source
- GFC-6 Q4 2025 Omada Health Inc Earnings Call. Earnings call transcript
- OM2 2025 Form 10-K. Annual report
- R14 Omada x Federated Insurance Case Study. Vendor-hosted named customer benefit evaluation